Figure 1
720 × 538px
· 240.9 केबी
Source Paper
Immunotherapy of Mild Cognitive Impairment by ω-3 Supplementation: Why Are Amyloid-β Antibodies and ω-3 Not Working in Clinical Trials?Cite This Figure
 > Source: Milan Fiala et al. "Immunotherapy of Mild Cognitive Impairment by ω-3 Supplementation: Why Are Amylo." *Journal of Alzheimer's disease : JAD*, 2018. PMID: [29103035](https://pubmed.ncbi.nlm.nih.gov/29103035/)
<figure> <img src="https://pdfs.citedhealth.com/figures/29103035/48.png" alt="Figure 1" /> <figcaption>Figure 1. Figure 1<br> Source: Milan Fiala et al. "Immunotherapy of Mild Cognitive Impairment by ω-3 Supplementation: Why Are Amylo." <em>Journal of Alzheimer's disease : JAD</em>, 2018. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/29103035/">29103035</a></figcaption> </figure>